Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-06-16 pm EDT			5-day change	1st Jan Change
807.58 ^USD	-1.44%		+4.90%	+4.61%

08:10pm	Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports	RE
08:10pm	Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports	RE

Top Midday Decliners

Published on 01/14/2025 at 13:34, updated on 01/14/2025 at 13:35

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Eli Lilly and Company

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports	08:10pm	RE
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports	08:10pm	RE
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports	07:43pm	RE
Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT	07:36pm	RE
Lilly will offer higher doses of Zepbound on its website	Jun. 16	RE
Lilly to offer highest doses of weight-loss drug Zepbound on website	Jun. 16	RE
Analyst recommendations: Meta, Eli Lilly, RTX Corp, Airbus, Roche…	Jun. 16
Lilly to offer highest doses of weight-loss drug Zepbound on website	Jun. 16	RE
Eli Lilly: a single price to expand access to Zepbound	Jun. 16	CF
Eli Lilly to Start Providing Higher-Dose Zepbound Variants	Jun. 16	MT
Lilly to offer higher dose versions of weight-loss drugs on website	Jun. 16	RE
Lilly to Offer All Approved Zepbound Doses via LillyDirect Self-Pay Pharmacy	Jun. 16	RE
Eli Lilly's Eloralintide Lowers Weight in Early-stage Trial	Jun. 15	MT
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	Jun. 13	RE
S&P 500 Suffers Weekly Drop as Israel, Iran Launch Attacks	Jun. 13	MT
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	Jun. 12	MT
India's OneSource eyes weight-loss drug boost to order book	Jun. 12	RE
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	Jun. 11	RE
Juvena Therapeutics and Eli Lilly and Company Enter Research Collaboration Focused on Muscle Health	Jun. 11	CI
Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials	Jun. 11	RE
Health Care Up on Sales Optimism -- Health Care Roundup	Jun. 10	DJ
Drug pricing reform talks with US government lack clarity, industry executives say	Jun. 10	RE
Drug pricing reform talks with US government lack clarity, industry executives say	Jun. 10	RE
Sector Update: Health Care Stocks Rise Late Afternoon	Jun. 10	MT
Lilly to Only Work With Telehealth Companies That Don't Sell Copycat Zepbound	Jun. 10	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

47,000

Sector

Pharmaceuticals

Calendar

Jun. 20 - American Diabetes Association Scientific Conference - Abstract No - 144-OR

More about the company